Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 4/2010

01-11-2010

Hepatitis B and the Immune System

Author: Kyong-Mi Chang

Published in: Current Hepatology Reports | Issue 4/2010

Login to get access

Abstract

As a persistent virus, hepatitis B virus (HBV) is believed to be noncytopathic in most circumstances, with its disease pathogenesis mediated by host innate and adaptive immune responses. Although HBV may initially avoid activating critical innate intracellular defenses (eg, type I interferons), T cells exert both cytopathic and noncytopathic antiviral effects toward resolution of HBV infection. With chronic HBV infection, various immune regulatory or tolerance mechanisms are induced with varying degrees of effector T-cell dysfunction and liver inflammation, which contributes to liver disease progression. This review highlights some components of host immune response relevant for HBV infection, including the more recent appreciation of immune regulatory mechanisms induced during chronic viral infection. Although therapeutic options are evolving for HBV, a better understanding of its immune pathogenetic and regulatory mechanisms may help develop better approaches to treat HBV infection and prevent disease progression.
Literature
1.
Palm NW, Medzhitov R: Pattern recognition receptors and control of adaptive immunity. Immunol Rev 2009, 227:221–233.CrossRefPubMed
2.
Jeannin P, Jaillon S, Delneste Y: Pattern recognition receptors in the immune response against dying cells. Curr Opin Immunol 2008, 20:530–537.CrossRefPubMed
3.
Chelbi-Alix MK, Wietzerbin J: Interferon, a growing cytokine family: 50 years of interferon research. Biochimie 2007, 89:713–718.CrossRefPubMed
4.
Sommereyns C, Paul S, Staeheli P, Michiels T: IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008, 4:e1000017.CrossRefPubMed
5.
Ge D, Fellay J, Thompson AJ, et al.: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399–401.CrossRefPubMed
6.
Thomas DL, Thio CL, Martin MP, et al.: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798–801.CrossRefPubMed
7.
Serbina NV, Jia T, Hohl TM, Pamer EG: Monocyte-mediated defense against microbial pathogens. Annu Rev Immunol 2008, 26:421–452.CrossRefPubMed
8.
9.
Adams DH, Ju C, Ramaiah SK, et al.: Mechanisms of immune-mediated liver injury. Toxicol Sci 2010, 115:307–321.CrossRefPubMed
10.
11.
Bryceson YT, Long EO: Line of attack: NK cell specificity and integration of signals. Curr Opin Immunol 2008, 20:344–352.CrossRefPubMed
12.
Boisvert J, Kunkel EJ, Campbell JJ, et al.: Liver-infiltrating lymphocytes in end-stage hepatitis C virus: subsets, activation status, and chemokine receptor phenotypes. J Hepatol 2003, 38:67–75.CrossRefPubMed
13.
Moretta A: The dialogue between human natural killer cells and dendritic cells. Curr Opin Immunol 2005, 17:306–311.CrossRefPubMed
14.
15.
16.
Wieland S, Thimme R, Purcell RH, Chisari FV: Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 2004, 101:6669–6674.CrossRefPubMed
17.
• Dunn C, Peppa D, Khanna P, et al.: Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009, 137:1289–1300. HBV displays interesting "stealth" characteristics with minimal transcriptional activation (including type I IFNs) during acute HBV infection in chimpanzees [16]. In this study of an unusual cohort of patients identified at preclinical stages of acute hepatitis B, IL-10 induction was associated with attenuated NK and T-cell function without type I IFN induction suggesting that HBV might induce immune regulatory pathways to suppress immune function (in addition to primary lack of type I IFN induction). CrossRefPubMed
18.
Lok AS, Ghany MG, Watson G, Ayola B: Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. J Viral Hepat 1998, 5:171–178.CrossRefPubMed
19.
Guidotti LG, Chisari FV: Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006, 1:23–61.CrossRefPubMed
20.
Hosel M, Quasdorff M, Wiegmann K, et al.: Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 2009, 50:1773–1782.CrossRefPubMed
21.
Guy CS, Mulrooney-Cousins PM, Churchill ND, Michalak TI: Intrahepatic expression of genes affiliated with innate and adaptive immune responses immediately after invasion and during acute infection with woodchuck hepadnavirus. J Virol 2008, 82:8579–8591.CrossRefPubMed
22.
• Fisicaro P, Valdatta C, Boni C, et al.: Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 2009, 58:974–982. This study provides a careful monitoring of early innate and adaptive immune responses in two patients identified early in the course of HBV infection with early activation of NK/NKT cells, further supporting the notion that HBV does not completely evade innate immune recognition in patients with acute hepatitis B (differing from the chimpanzee model). CrossRefPubMed
23.
Oliviero B, Varchetta S, Paudice E, et al.: Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 2009, 137:1151–1160.CrossRefPubMed
24.
Dunn C, Brunetto M, Reynolds G, et al.: Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 2007, 204:667–680.CrossRefPubMed
25.
van der Molen RG, Sprengers D, Biesta PJ, et al.: Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. Hepatology 2006, 44:907–914.CrossRefPubMed
26.
Zhang Z, Zhang H, Chen D, et al.: Response to interferon-alpha treatment correlates with recovery of blood plasmacytoid dendritic cells in children with chronic hepatitis B. J Hepatol 2007, 47:751–759.CrossRefPubMed
27.
Casadevall A, Pirofski LA: A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv Immunol 2006, 91:1–44.CrossRefPubMed
28.
Bouaziz JD, Yanaba K, Tedder TF: Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 2008, 224:201–214.CrossRefPubMed
29.
Hayata T, Nakano Y, Yoshizawa K, et al.: Effects of interferon on intrahepatic human leukocyte antigens and lymphocyte subsets in patients with chronic hepatitis B and C. Hepatology 1991, 13:1022–1028.CrossRefPubMed
30.
Lobo-Yeo A, Senaldi G, Portmann B, et al.: Class I and class II major histocompatibility complex antigen expression on hepatocytes: a study in children with liver disease. Hepatology 1990, 12:224–232.CrossRefPubMed
31.
Knolle PA, Gerken G: Local control of the immune response in the liver. Immunol Rev 2000, 174:21–34.CrossRefPubMed
32.
Chisari FV, Isogawa M, Wieland SF: Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 2010 (Epub ahead of print).
33.
Maini MK, Boni C, Lee CK, et al.: The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000, 191:1269–1280.CrossRefPubMed
34.
Maini MK, Boni C, Ogg GS, et al.: Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology 1999, 117:1386–1396.CrossRefPubMed
35.
Penna A, Artini M, Cavalli A, et al.: Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996, 98:1185–1194.CrossRefPubMed
36.
Limmer A, Ohl J, Kurts C, et al.: Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med 2000, 6:1348–1354.CrossRefPubMed
37.
Bowen DG, Zen M, Holz L, et al.: The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J Clin Invest 2004, 114:701–712.PubMed
38.
Moriyama T, Guilhot S, Klopchin K, et al.: Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 1990, 248:361–364.CrossRefPubMed
39.
Thimme R, Wieland S, Steiger C, et al.: CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003, 77:68–76.CrossRefPubMed
40.
Rehermann B, Nascimbeni M: Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005, 5:215–229.CrossRefPubMed
41.
Rehermann B, Chang KM, McHutchinson J, et al.: Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 1996, 70:7092–7102.PubMed
42.
Rehermann B, Ferrari C, Pasquinelli C, Chisari FV: The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996, 2:1104–1108.CrossRefPubMed
43.
Rehermann B, Lau D, Hoofnagle JH, Chisari FV: Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996, 97:1655–1665.CrossRefPubMed
44.
Rehermann B, Fowler P, Sidney J, et al.: The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. JExpMed 1995, 181:1047–1058.CrossRef
45.
Webster GJ, Reignat S, Brown D, et al.: Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004, 78:5707–5719.CrossRefPubMed
46.
Heathcote J, McHutchison J, Lee S, et al.: A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 1999, 30:531–536.CrossRefPubMed
47.
Sitia G, Isogawa M, Iannacone M, et al.: MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J Clin Invest 2004, 113:1158–1167.PubMed
48.
Das A, Hoare M, Davies N, et al.: Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med 2008, 205:2111–2124.CrossRefPubMed
49.
Franco A, Guidotti LG, Hobbs MV, et al.: Pathogenetic effector function of CD4-positive T helper 1 cells in hepatitis B virus transgenic mice. J Immunol 1997, 159:2001–2008.PubMed
50.
• Asabe S, Wieland SF, Chattopadhyay PK, et al.: The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 2009, 83:9652–9662. In this interesting study, viral inoculum (high and low) contributed to the outcome of HBV infection in HBV-infected chimpanzees in vivo by priming CD4 T cells. CD4 T cells were also shown to play a critical role in the outcome of HBV infection because CD4 depletion prior to HBV infection resulted in viral persistence with poor antiviral CD8 T-cell response. CrossRefPubMed
51.
52.
• Boni C, Fisicaro P, Valdatta C, et al.: Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007, 81:4215–4225. This study showed that dysfunctional HBV-specific CD8 T cells in chronic HBV patients express increased PD-1 and their function can be improved by blocking PD-1:PD-L1 pathway. These findings suggest that PD-1 contributes to HBV-specific T-cell dysfunction in HBV persistence and raises a possibility for potential immunotherapeutic strategies for chronic hepatitis B involving PD-1. CrossRefPubMed
53.
Urbani S, Amadei B, Tola D, et al.: PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 2006, 80:11398–11403.CrossRefPubMed
54.
Nakamoto N, Cho H, Shaked A, et al.: Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog 2009, 5:e1000313.CrossRefPubMed
55.
Chang KM: Regulatory T cells and the liver: a new piece of the puzzle. Hepatology 2005, 41:700–702.CrossRefPubMed
56.
Kaplan DE, Ikeda F, Li Y, et al.: Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis. J Hepatol 2008, 48:903–913.CrossRefPubMed
57.
Sakaguchi S, Miyara M, Costantino CM, Hafler DA: FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010, 10:490–500.CrossRefPubMed
58.
Rouse BT, Suvas S: Regulatory cells and infectious agents: detentes cordiale and contraire. J Immunol 2004, 173:2211–2215.PubMed
59.
Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057–1061.CrossRefPubMed
60.
61.
Quezada SA, Peggs KS, Curran MA, Allison JP: CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006, 116:1935–1945.CrossRefPubMed
62.
Roncarolo MG, Gregori S, Battaglia M, et al.: Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006, 212:28–50.CrossRefPubMed
63.
Brooks DG, Trifilo MJ, Edelmann KH, et al.: Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006, 12:1301–1309.CrossRefPubMed
64.
Ejrnaes M, Filippi CM, Martinic MM, et al.: Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 2006, 203:2461–2472.CrossRefPubMed
65.
Chen W, Jin W, Hardegen N, et al.: Conversion of peripheral CD4 + CD25- naive T cells to CD4 + CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003, 198:1875–1886.CrossRefPubMed
66.
Bataller R, Brenner DA: Liver fibrosis. J Clin Invest 2005, 115:209–218.PubMed
67.
Ebinuma H, Nakamoto N, Li Y, et al.: Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. J Virol 2008, 82:5043–5053.CrossRefPubMed
68.
Brown JA, Dorfman DM, Ma FR, et al.: Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003, 170:1257–1266.PubMed
69.
Kido M, Watanabe N, Okazaki T, et al.: Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling. Gastroenterology 2008, 135:1333–1343.CrossRefPubMed
70.
Boettler T, Panther E, Bengsch B, et al.: Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8+ T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. J Virol 2006, 80:3532–3540.CrossRefPubMed
71.
Vandepapeliere P, Lau GK, Leroux-Roels G, et al.: Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007, 25:8585–8597.CrossRefPubMed
72.
Thio CL, Mosbruger TL, Kaslow RA, et al.: Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol 2004, 78:11258–11262.CrossRefPubMed
73.
Stoop JN, van der Molen RG, Baan CC, et al.: Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005, 41:771–778.CrossRefPubMed
74.
Franzese O, Kennedy PT, Gehring AJ, et al.: Modulation of the CD8 + -T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol 2005, 79:3322–3328.CrossRefPubMed
75.
Xu D, Fu J, Jin L, et al.: Circulating and liver resident CD4 + CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006, 177:739–747.PubMed
76.
Fu J, Xu D, Liu Z, et al.: Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007, 132:2328–2339.CrossRefPubMed
77.
Hyodo N, Nakamura I, Imawari M: Hepatitis B core antigen stimulates interleukin-10 secretion by both T cells and monocytes from peripheral blood of patients with chronic hepatitis B virus infection. Clin Exp Immunol 2004, 135:462–466.CrossRefPubMed
78.
Bertoletti A, D'Elios MM, Boni C, et al.: Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 1997, 112:193–199.CrossRefPubMed
79.
80.
Chisari FV: Hepatitis B virus transgenic mice: insights into the virus and the disease. Hepatology 1995, 22(4 Pt 1):1316–1325.PubMed
81.
82.
Lopes AR, Kellam P, Das A, et al.: Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J Clin Invest 2008, 118:1835–1845.CrossRefPubMed
83.
Bertoletti A, Sette A, Chisari FV, et al.: Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994, 369:407–410.CrossRefPubMed
84.
Chen M, Sallberg M, Hughes J, et al.: Immune tolerance split between hepatitis B virus precore and core proteins. J Virol 2005, 79:3016–3027.CrossRefPubMed
85.
Bertoletti A, Maini M, Williams R: Role of hepatitis B virus specific cytotoxic T cells in liver damage and viral control. Antiviral Res 2003, 60:61–66.CrossRefPubMed
86.
Gehring AJ, Sun D, Kennedy PT, et al.: The level of viral antigen presented by hepatocytes influences CD8 T-cell function. J Virol 2007, 81:2940–2949.CrossRefPubMed
87.
Boni C, Penna A, Ogg GS, et al.: Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001, 33:963–971.CrossRefPubMed
88.
Mizukoshi E, Sidney J, Livingston B, et al.: Cellular immune responses to the hepatitis B virus polymerase. J Immunol 2004, 173:5863–5871.PubMed
Metadata
Title
Hepatitis B and the Immune System
Author
Kyong-Mi Chang
Publication date
01-11-2010
Publisher
Current Science Inc.
Published in
Current Hepatology Reports / Issue 4/2010
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-010-0051-5

Other articles of this Issue 4/2010

Current Hepatology Reports 4/2010 Go to the issue

ReviewPaper

The Role of Interferon in Hepatitis B Therapy

ReviewPaper

Hepatitis B Biomarkers: Clinical Significance of the Old and the New

ReviewPaper

Hepatitis C and End-stage Liver Disease

ReviewPaper

Delta Hepatitis: Forgotten, but Not Gone

ReviewPaper

Antiviral Therapy: Analysis of Long-term Efficacy and Safety

ReviewPaper

Current Concepts of HBV/HCV Coinfection: Coexistence, but Not Necessarily in Harmony
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits